Superbugs: Low-income countries must not be left behind

Dr Marc Sprenger
WHO Director, Antimicrobial Resistance Secretariat

Commentary

“While the world has woken up to the threat of antimicrobial resistance and is starting to respond, many low-income countries are struggling to find capacity and need greater support. That is the headline finding of a groundbreaking global survey of how well countries think they are doing in fighting antimicrobial resistance, conducted by the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO), and the World Organisation for Animal Health (OIE).

Dr Marc Sprenger, WHO Director, Antimicrobial Resistance Secretariat

Bacteria are rapidly developing resistance to antibiotics. Viruses, fungi and parasites are doing the same. This is because we have been overusing and misusing medicines for decades. It’s called antimicrobial resistance, and it is a major global threat.

This silent tsunami, in which we are losing our ability to protect against infections such as pneumonia, tuberculosis and malaria, has been neglected for far too long. For years, microbiologists have been warning—with increasing volume—that indiscriminate use of antibiotics and similar drugs in humans and animals is increasingly rendering them ineffective.

Now, antimicrobial resistance has finally come to the forefront in health and political circles, leading to the development in 2015 of a Global Action Plan, endorsed by Ministers of Health and Agriculture at the governing bodies of WHO, FAO and OIE, and Heads of State at a high-level meeting of the UN General Assembly last September. Since then, countries have been developing national action plans to put the globally-agreed policy changes into practice.

Our survey of country progress offers some good news. More than 90% of people in the world (6.5 billion) live in a country that has developed, or is developing, a national action plan on antimicrobial resistance. Some of the key areas in which countries report that they are doing well are: training doctors, nurses, and other health workers on how to reduce the spread of antimicrobial resistance; improving the prevention and control of infections; and strengthening systems to detect the extent of the problem. These are incredible achievements. National plans are multisectoral—which means that leaders in human health, animal health, and the environment, who often talk about joined-up approaches, are actually putting it into action.

When you drill down into the numbers, a slightly less rosy picture emerges. High-income countries that already have stronger health and agricultural systems are much better prepared to deal with antimicrobial resistance—more than 80% of these countries have a plan in place, or are developing one. By contrast, about 30% of low-income countries either have or are developing a plan. This is not surprising. Many low-income countries lack the expertise or capacity to develop a national plan, or they are overwhelmed by dealing with fragile health systems or outbreaks of infectious diseases.

Yet low-income countries are the ones that need to be the best prepared since they are likely to bear the brunt of resistance: infectious diseases are much more common, and their health systems are much weaker and less able to adapt as first-line antibiotics (which tend to be cheaper) become less effective. The burden of harder-to-treat infectious diseases and the impact of treatment failure in human lives and relative economic cost will be much higher than in richer countries.

The lack of preparedness in low-income countries should concern us all, no matter how rich a country we live in. Antibiotic resistance will not just affect the ability to treat diseases such as malaria or tuberculosis, which many might think occur in the poorest parts of the world. Resistant bacteria will challenge our ability to treat women in childbirth, people undergoing surgery, or those on cancer chemotherapy. And, in a globalized world, microbes don’t respect national borders. They spread with ease.”

More >>>

Global partnership launched to prevent epidemics with new vaccines

A global coalition to create new vaccines for emerging infectious diseases, designed to help give the world an insurance policy against epidemics, launches today [18th Jan 2017] at the World Economic Forum in Davos, Switzerland.

With an initial investment of US$460m from the governments of Germany, Japan and Norway, plus the Bill & Melinda Gates Foundation and the Wellcome Trust, CEPI – the Coalition for Epidemic Preparedness Innovations will seek to outsmart epidemics by developing safe and effective vaccines against known infectious disease threats that could be deployed rapidly to contain outbreaks, before they become global health emergencies.

CEPI also hopes to shorten the time it takes to develop new vaccines to protect against viruses that emerge suddenly as public health threats, as Zika did recently, by capitalising on exciting developments in adaptable vaccine technology and investing in facilities that could respond quickly to previously unknown pathogens.

Today’s financial commitments mean that CEPI has raised almost half of the $1bn it needs for its first five years, and it is now calling for proposals from researchers and companies around the world to support the development of vaccines against its first target diseases.

CEPI will initially target the MERS-CoV, Lassa and Nipah viruses, which have known potential to cause serious epidemics. It aims to develop two promising vaccine candidates against each of these diseases before any epidemic, so these are available without delay if and when an outbreak begins. CEPI will also scope out potential support for vaccines against multiple strains of the Ebola and Marburg viruses, and Zika.

To achieve all these goals, CEPI will need significant additional investment, and the initial CEPI funders are calling today for other governments and philanthropic organisations to join them in helping to protect the world against future epidemics. CEPI is looking to complete its fundraising by the end of 2017.

Erna Solberg, Prime Minister of Norway, said: “Just over a year ago 193 states adopted the Sustainable Development Goals – the roadmap for the future we want. Epidemics threaten that future. They can ruin societies on a scale only matched by wars and natural disasters. They respect no borders and don’t care if we are rich or poor. Protecting the vulnerable is protecting ourselves. This is why we all must work together to be better prepared – and why my Government is fully committed to ensure that CEPI achieves its mission.”

Bill Gates, Co-chair of the Bill and Melinda Gates Foundation, said: “Ebola and Zika showed that the world is tragically unprepared to detect local outbreaks and respond quickly enough to prevent them from becoming global pandemics. Without investments in research and development, we will remain unequipped when we face the next threat.

“The ability to rapidly develop and deliver vaccines when new ‘unknown’ diseases emerge offers our best hope to outpace outbreaks, save lives and avert disastrous economic consequences. CEPI is a great example of how supporting innovation and R&D can help the world to address some of its most pressing health challenges.”

Dr Jeremy Farrar, Director of the Wellcome Trust, said: “We know from Ebola, Zika and SARS that epidemics are among the significant threats we face to life, health and prosperity. Vaccines can protect us, but we’ve done too little to develop them as an insurance policy. CEPI is our chance to learn the lessons of recent tragedies, and outsmart epidemics with new vaccine defences. If others join us in supporting CEPI, we can realise our goal of creating a safer world.”

CEPI is a direct response to calls from four independent expert reports into the Ebola epidemic for a new system for stimulating the development of vaccines against epidemic threats. It was founded by the governments of India and Norway, the Bill & Melinda Gates Foundation, Wellcome and the World Economic Forum, which has played a key convening role, bringing together stakeholders at the 2016 Davos meeting and other events.

CEPI is also backed by major pharmaceutical corporations, the World Health Organization and Médecins Sans Frontières / Doctors Without Borders, as well as philanthropies and leading academic vaccine research groups.

The Government of India is currently finalising the level of a significant funding commitment to CEPI. In addition to financing for vaccine development that will be available through CEPI’s pooled fund, the European Commission will contribute to CEPI’s objectives and plans to co-fund actions with CEPI, such as through the Innovative Medicines Initiative (IMI).

More…